G&E Herbal Biotechnology Co., Ltd.

Taipei Exchange 4911.TWO

G&E Herbal Biotechnology Co., Ltd. Gross Profit Margin for the year ending December 31, 2023: 79.69%

G&E Herbal Biotechnology Co., Ltd. Gross Profit Margin is 79.69% for the year ending December 31, 2023, a 30.82% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • G&E Herbal Biotechnology Co., Ltd. Gross Profit Margin for the year ending December 31, 2022 was 60.91%, a 55.50% change year over year.
  • G&E Herbal Biotechnology Co., Ltd. Gross Profit Margin for the year ending December 31, 2021 was 39.17%, a -7.95% change year over year.
  • G&E Herbal Biotechnology Co., Ltd. Gross Profit Margin for the year ending December 31, 2020 was 42.56%, a 229.27% change year over year.
  • G&E Herbal Biotechnology Co., Ltd. Gross Profit Margin for the year ending December 31, 2019 was -32.92%.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Taipei Exchange: 4911.TWO

G&E Herbal Biotechnology Co., Ltd.

CEO Mr. Kou-Wha Kou Ph.D.
IPO Date March 21, 2011
Location
Headquarters No.92, Keji 5th Road
Employees 37
Sector Health Care
Industries
Biotechnology Cosmetics Pharmaceuticals
Description

G&E Herbal Biotechnology Co., Ltd., a biopharmaceutical company, focuses on the development and commercialization of novel botanical extraction technology and products. It offers botanical anti-aging cosmetic products, such as facial foam cleanser and cleansing essence, botanical extract toner, lightening lotion, essential oil, and moisturizing serum and cream; SR-100 botanical essence and bromelain illuminating cleansing mousse; and hepato protective agent capsules. The company also provides botanical healthcare products comprising ArthrEnergy, Jujubes Polysaccharide, Diabecut, HepatoClean, Astragali Radix, Goji, Prosta, and SR-100 capsules; and adult products. In addition, it is developing Solarise injection for the treatment of gynecologic, head, and neck cancer; Apocin capsule to treat non-small cell lung cancer; and SR-T100 Gel for the treatment of common and genital warts. Further, the company manufactures technology development for various dietary supplements, as well as provides technical advisory services to other biotechnology organizations. G&E Herbal Biotechnology Co., Ltd. was founded in 2002 and is based in Tainan City, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email